Synergistic neutralization of simian-human immunodeficiency virus SHIV- vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins

Journal of Virology

Volumn 72, Issue 4, 1998, Pages 3235-3240

  Li, An ^a,b   Katinger, Hermann ^c   Posner, Marshall R ^b,d   Cavacini, Lisa ^b,d   Zolla Pazner, Susan ^e   Gorny, Miroslaw K ^e   Sodroski, Joseph ^a,b   Chou, Ting Chao ^f   Baba, Timothy W ^a,b,g   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENVELOPE PROTEIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN; VPU PROTEIN;

ANIMAL CELL; ARTICLE; BINDING SITE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPROPHYLAXIS; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS NEUTRALIZATION;

EID: 0031897793     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.4.3235-3240.1998     Document Type: Article

References (51)

1. sm infection in cynomolgus monkeys by active or passive immunization. AIDS Res. Hum. Retroviruses 8:1511-1513.
2. Buchbinder, A., S. Karwowska, M. K. Gorny, S. T. Burda, and S. Zolla-Pazner. 1992. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res. Hum. Retroviruses 8:425-427. (Letter.)
3. Burkly, L. C., N. Mulrey, R. Blumenthal, and D. S. Dimitrov. 1995. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J. Virol. 69:4267-4273.
4. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
5. Cavacini, L. A., C. I. Emes, J. Power, J. Unerdahl, R. Goldstein, K. K. Mayer, and M. R. Posner. 1993. Loss of serum antibodies to a conformational epitope of HIV-1/gp 120 identified by a human monoclonal antibody is associated with disease progression. J. Acquired Immune Defic. Syndr. 6:1093-1102.
6. Cavacini, L. A., C. L. Emes, J. Power, A. Buchbinder, S. Zolla-Pazner, and M. R. Posner. 1993. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J. Acquired Immune Defic. Syndr. 6:6353-6358.
7. Chou, T.-C., and P. Talalay. 1981. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115: 207-216.
8. Chou, T.-C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
9. Chou, J., and T.-C. Chou. 1987. Dose-effect analysis with microcomputers: quantitation of ED50, LD50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics. Manual and software. Biosoft, Cambridge, United Kingdom.
10. Chou, T.-C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-102. In T.-C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, San Diego, Calif.
11. Chou, T.-C., and M. Hayball. 1996. CalcuSyn for Windows. Multiple-drug dose-effect analyzer and manual. Biosoft, Cambridge, United Kingdom.
12. Conley, A. J., J. A. Kessler II, L. J. Boots, J.-S. Tung, B. A. Arnold, P. M. Keller, A. R. Shaw, and E. A. Emini. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91:3348-3352.
13. Conley, A. J., J. A. Kessler II, L. J. Boots, P. M. Mckenna, W. A. Schleif, E. A. Emini, G. E. III Mark, H. Katinger, E. K. Cobb, S. M. Lunceford, S. R. Rouse, and K. K. Murthy. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:6751-6758.
14. Dunn, C. S., C. Beyer, M. P. Kieny, L. Gloeckler, D. Schmitt, J. P. Gut, A. Kirn, and A. M. Aubertin. 1996. High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai. Virology 223:351-361.
15. Emini, E. A., W. A. Schleif, J. H. Nunberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, J. W. Eichberg, and K. K. Murthy. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730.
16. Franchini, G., C. Gurgo, and H. G. Guo. 1987. Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency virus. Nature 328:539-543.
17. Gardner, M., A. Rosenthal, M. Jennings, J. A. Yee, L. Antipa, and M. Mackenzie. 1994. Passive immunization of macaques against SIV infection. J. Med. Primatol. 23:164-174.
18. Gardner, M., A. Rosenthal, M. Jennings, J. A. Yee, L. Antipa, and E. Robinson, Jr. 1995. Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res. Hum. Retroviruses 11:843-854.
19. Goff, S., P. Traktman, and D. Baltimore. 1981. Isolation and properties of Moloney murine leukemia virus: use of a rapid assay for release of virion reverse transcriptase. J. Virol. 38:239-248.
20. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J. Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
21. Gorny, M. K., J. Y. Xu, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635-643.
22. Ho, D. D., J. A. McKeating, X. L. Li, T. Moodgil, E. S. Daar, N. C. Sun, and J. E. Robinson. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:489-493.
23. Jahaverian, K., A. J. Langlois, F. J. LaRosa, A. T. Profy, D. P. Bolognesi, W. C. Herlihy, S. D. Putney, and T. J. Matthews. 1990. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250:1590-1593.
24. + T cells and AIDS in pig-tailed macaques. J. Virol. 70:3189-3197.
25. Karwowska, S., M. K. Gorny, A. Buchbinder, V. Gianakakos, C. Williams, T. Fuerst, and S. Zolla-Pazner. 1992. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res. Hum. Retroviruses 8:1099-1106.
26. mac251. AIDS Res. Hum. Retroviruses 10:189-194.
27. Laal, S., S. Burda, M. K. Gorny, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1994. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol. 68:4001-4008.
28. Lewis, M. G., W. R. Elkins, F. E. McCutchan, R. E. Benverniste, C. Y. Lai, D. C. Montefiori, D. S. Burke, G. A. Eddy, and A. Shafferman. 1993. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine 11:1347-1355.
29. Li, A., T. W. Baba, J. Sodroski, S. Zolla-Pazner, M. K. Gorny, J. Robinson, R. Posner, H. Katinger, C. F. Barbas III, D. R. Burton, T.-C. Chou, and R. M. Ruprecht. 1997. Synergistic neutralization of a chimeric SIV/HIV-1 virus with combinations of human anti-HIV-1 envelope monoclonal antibodies or hyper immune globulins. AIDS Res. Hum. Retroviruses 13:647-656.
30. La, Y., M. S. Salvato, C. D. Pauza, J. T. Li, J. Sodroski, K. Manson, M. Wyand, N. L. Letvin, S. Jenkins, N. Touzjian, C. Chutkowski, N. Kushner, M. LeFaile, L. G. Payne, and B. Roberts. 1996. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J. Acquired Immune Defic. Synd. Hum. Retrovirol. 12:99-106.
31. Matthews, T., A. Langlois, W. Robey, N. Chang, R. Gallo, R. Fischinger, and D. Bolognesi. 1986. Restricted neutralization of divergent human T-lymphotropic virus type III isolated by antibodies to the major envelope glycoprotein. Proc. Natl. Acad. Sci. USA 83:9709-9713.
32. Mioe, C. E., S. Su, P. Chigurupati, S. Burda, C. Williams, M. K. Gorny, and S. Zolla-Pazner. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol., in press.
33. Montefiori, D. C., W. B. Robinson, Jr., and S. S. Schuffman. 1988. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:231-235.
34. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
35. Muster, T., R. Guinea, A. Trkola, M. Purtscher, A. Klima, F. Steindl, P. Palese, and H. Katinger. 1994. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKEAS. J. Virol. 68:4031-4034.
36. Ohno, T., M. Terada, Y. Yoneda, K. W. Shea, R. F. Chambers, D. M. Stroka, M. Nakamura, and D. W. Kufe. 1991. A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. Proc. Natl. Acad. Sci. USA 88:10726-10729.
37. Posner, M. R., T. Hideshina, T. Cannon, M. Mukherjee, K. H. Mayer, and R. A. Byrn. 1991. An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. J Immunol. 146:4325-4332.
38. Posner, M. R., L. A. Cavacini, C. L. Emes, J. Power, and R. A. Byrn. 1993. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J. Acquired Immune Defic. Syndr. 6:7-14.
39. sm, infection by passive immunization in cynomolgus monkeys. Nature 352:436-438.
40. Reimann, K. A., J. T. Li, G. Voss, C. Lekutis, K. Tenner-Racz, P. Racz, W. Lin, D. C. Montefiori, D. E. Lee-Parritz, Y. Lu, R. G. Collman, J. Sodroski, and N. L. Letvin. 1996. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70:3198-3206.
41. Reimann, K. A., J. T. Li, R. Veazey, M. Halloran, I. W. Park, G. B. Karlsson, J. Sodroski, and N. L. Letvin. 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:6922-6928.
42. Rusche, J. R., K. Javaherian, C. McDanal, J. Petro, D. L. Lynn, R. Grimaila, A. Langlois, R. C. Gallo, L. O. Arthur, P. J. Fischinger, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1988. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino-acid sequence of the viral envelope gp120. Proc. Natl. Acad. Sci. USA 85:3198-3202.
43. agm infection in the African green monkey natural host. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:217-226.
44. Spear, G. T., D. M. Takefman, B. L. Sullivan, A. L. Landay, and S. Zollar-Pazner. 1993. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J. Virol. 67:53-59.
45. Thali, M., C. Furman, B. Wahren, M. Posner, D. D. Ho, J. Robinson, and J. Sodroski. 1992. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J. Acquired Immune Defic. Syndr. 5:591-599.
46. Tilley, S. A., W. J. Honnen, M. E. Racho, M. Hilgartner, and A. Pinter. 1991. A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res. Virol. 142:247-259.
47. Tilley, S. A., W. J. Honnen, M. E. Racho, T.-C. Chou, and A. Pinter. 1992. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res. Hum. Retroviruses 8:461-467.
48. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas III, D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
49. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108.
50. Vijh-Warrier, S., A. Pinter, W. J. Honnen, and S. Tilley. 1996. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J. Virol. 70:4466-4473.
51. Wyatt, R., M. Thali, S. Tilley, A. Pinter, M. R. Posner, D. D. Ho, J. Robinson, and J. Sodroski. 1992. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J. Virol. 66:6997-7004.